InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% – Should You Buy?

InflaRx N.V. (NASDAQ:IFRX)’s share price rose 32.5% during mid-day trading on Friday . The company traded as high as $1.67 and last traded at $1.59. Approximately 7,901,957 shares changed hands during trading, an increase of 1,302% from the average daily volume of 563,467 shares. The stock had previously closed at $1.20.

Wall Street Analysts Forecast Growth

IFRX has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of InflaRx in a research note on Tuesday, December 30th. Guggenheim cut their price target on InflaRx from $22.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. Finally, Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.17.

InflaRx Trading Up 32.5%

The stock has a 50 day moving average of $0.95 and a 200-day moving average of $1.09. The company has a market capitalization of $114.94 million, a P/E ratio of -2.09 and a beta of 1.49.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Friday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). The company had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.03 million. As a group, sell-side analysts expect that InflaRx N.V. will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC grew its stake in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the period. HRT Financial LP bought a new position in shares of InflaRx during the 4th quarter valued at approximately $47,000. Concurrent Investment Advisors LLC grew its stake in shares of InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares during the period. Insigneo Advisory Services LLC bought a new position in shares of InflaRx during the 4th quarter valued at approximately $61,000. Finally, Quadrature Capital Ltd bought a new position in shares of InflaRx during the 4th quarter valued at approximately $104,000. 42.39% of the stock is currently owned by institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.